Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides “Quality Affordable Healthcare Products®” across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China.

Type
Public
HQ
Dublin, IE
Founded
1887
Size (employees)
13,300 (est)
Perrigo was founded in 1887 and is headquartered in Dublin, IE
Report incorrect company information

Perrigo Office Locations

Perrigo has offices in Dublin and Allegan
Dublin, IE (HQ)
2 Lower Grand Canal St
Allegan, US
515 Eastern Ave
Show all (2)
Report incorrect company information

Perrigo Financials and Metrics

Perrigo Financials

Perrigo's revenue was reported to be $1.33 b in FY, 2016 which is a 71.1% decrease from the previous period.
USD

Revenue (Q1, 2018)

1.2 b

Gross profit (Q1, 2018)

464.4 m

Gross profit margin (Q1, 2018), %

38.9%

Net income (Q1, 2018)

71.6 m

EBIT (Q1, 2018)

128.5 m

Market capitalization (31-Oct-2017)

11.6 b

Closing share price (31-Oct-2017)

83.7

Cash (1-Apr-2017)

3.1 b
Perrigo's current market capitalization is $11.6 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

4.1 b4.6 b1.3 b

Revenue growth, %

13%(71%)

Cost of goods sold

2.9 b

Gross profit

1.7 b
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

1.3 b1.4 b1.5 b1.4 b1.2 b

Cost of goods sold

795.9 m860.3 m913.8 m848.6 m729.6 m

Gross profit

548.8 m522.9 m567.2 m506.3 m464.4 m

Gross profit Margin, %

41%38%38%37%39%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

799.5 m785.6 m622.3 m

Accounts Receivable

935.1 m1.3 b

Inventories

631.6 m838.9 m795 m

Current Assets

2.6 b3.2 b2.8 b
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

609.4 m891.5 m3.6 b506.5 m588.9 m641.8 m362.7 m3.1 b

Accounts Receivable

869.4 m924.7 m

Inventories

693.5 m656.8 m641.8 m637 m888 m868.8 m894.6 m884.6 m800.2 m

Current Assets

2.3 b2.6 b5.4 b5.1 b2.9 b3 b3 b2.6 b5.1 b
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(205.3 m)128 m42.5 m

Depreciation and Amortization

358.9 m548.8 m182.4 m

Inventories

83 m10.7 m(29.6 m)

Accounts Payable

(24.9 m)140.6 m(194.1 m)
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

48.1 m96.3 m70.2 m(94.9 m)112.6 m(334.6 m)(140.3 m)(1.4 b)71.6 m

Depreciation and Amortization

175.4 m182.5 m369.3 m556.3 m109.4 m

Inventories

(57 m)(14.8 m)(50.3 m)(29.9 m)500 k

Accounts Payable

(194 m)300 k(41.1 m)(51.8 m)2.5 m
USDY, 2017

Financial Leverage

2.3 x
Show all financial metrics
Report incorrect company information

Perrigo News and Updates

Drugs for Vulvovaginal Candidiasis Market Trends, Supply, Demand, Analysis by Industry Professionals | Perrigo, Pfizer, Effik, Teva, Sanofi

HTF MI recently broadcasted a new study in its database that highlights the in-depth market analysis with future prospects of Drugs for Vulvovaginal Candidiasis market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Infant Formula Milk Powder 2018 Global Market Key Players -Meiji, Perrigo, Biostime, Mead Johnson, HiPP, Heinz -Analysis And Forecast To 2022

Wiseguyreports.Com Adds “Infant Formula Milk Powder-Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Nonallergic Rhinitis Market CAGR of 5.3% Trending Demand by Key Types and Major Regions Till 2023

Nonallergic Rhinitis Market is segmented into physical examination, allergy testing, imaging test, and others. Allergy testing is further segmented into skin test, and blood test. Imaging test is further segmented into nasal endoscopy, and computerized tomography (CT) Scan. Posted via Industry Today…

SK Capital closes Perrigo API buy

SK Capital said Nov. 21 that completed its buy of Perrigo Co plc’s active pharmaceutical ingredients business. The deal was announced in August. The API unit was renamed Wavelength Pharmaceuticals.

Infant Formula Milk Powder Industry 2017 Global Market By Segment, Types, Regions, Applications And Forecast To 2022

Wiseguyreports.Com Adds “Infant Formula Milk Powder-Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

SK Capital to buy Perrigo API

SK Capital has agreed to acquire Perrigo API, an Israeli maker of generic active pharmaceutical ingredients and finished dose forms. No financial terms were disclosed. The deal is expected to close in the fourth quarter of this year. RBC Capital Markets LLC and Rothschild served as buyside advisers …
Show more
Report incorrect company information